Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group.

N Engl J Med. 2006 Oct 5;355(14):1432-44.

2.

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group.

Ophthalmology. 2009 Jan;116(1):57-65.e5. doi: 10.1016/j.ophtha.2008.10.018.

PMID:
19118696
3.

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY; FOCUS Study Group.

Arch Ophthalmol. 2006 Nov;124(11):1532-42. Erratum in: Arch Ophthalmol. 2007 Jan;125(1):138.

PMID:
17101999
4.

Ranibizumab for neovascular age-related macular degeneration.

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group.

N Engl J Med. 2006 Oct 5;355(14):1419-31.

5.

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.

Kourlas H, Abrams P.

Clin Ther. 2007 Sep;29(9):1850-61. Review.

PMID:
18035187
6.

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.

Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A; DENALI Study Group.

Ophthalmology. 2012 May;119(5):1001-10. doi: 10.1016/j.ophtha.2012.02.003. Epub 2012 Mar 22.

PMID:
22444829
7.

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.

Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A; MONT BLANC Study Group.

Ophthalmology. 2012 May;119(5):992-1000. doi: 10.1016/j.ophtha.2012.02.002. Epub 2012 Mar 17.

PMID:
22424834
8.

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.

Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group.

Am J Ophthalmol. 2008 May;145(5):862-74. doi: 10.1016/j.ajo.2007.12.029. Epub 2008 Mar 5.

PMID:
18321465
9.

Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.

Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J; Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group.

Arch Ophthalmol. 2009 Jan;127(1):13-21. doi: 10.1001/archophthalmol.2008.562.

PMID:
19139332
10.

Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.

Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators.

BMJ. 2010 Jun 9;340:c2459. doi: 10.1136/bmj.c2459.

11.
12.

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.

Spielberg L, Leys A.

Graefes Arch Clin Exp Ophthalmol. 2010 Jul;248(7):943-56. doi: 10.1007/s00417-009-1256-6. Epub 2010 Mar 4.

PMID:
20204659
13.

Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.

Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR.

Am J Ophthalmol. 2007 Dec;144(6):850-857. Epub 2007 Oct 22.

PMID:
17949673
15.

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.

Vedula SS, Krzystolik MG.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005139. doi: 10.1002/14651858.CD005139.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;8:CD005139.

16.

Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.

Kaiser PK; Registry of Visudyne AMD Therapy Writing Committee, Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter JS, Samuel M, Tolentino MJ, Roth D, Sheidow T, Strong HA.

Ophthalmology. 2009 Apr;116(4):747-55, 755.e1. doi: 10.1016/j.ophtha.2008.12.057. Epub 2009 Feb 25.

PMID:
19243834
18.

Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.

Bressler NM, Chang TS, Varma R, Suñer I, Lee P, Dolan CM, Ward J, Ianchulev T, Fine J.

Ophthalmology. 2013 Jan;120(1):160-8. doi: 10.1016/j.ophtha.2012.07.027. Epub 2012 Sep 23.

PMID:
23009891
19.

EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.

Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH.

Retina. 2012 Sep;32(8):1453-64.

PMID:
22426346
20.

Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation.

Seidel G, Werner C, Weger M, Steinbrugger I, Haas A.

Acta Ophthalmol. 2013 Sep;91(6):e482-5. doi: 10.1111/aos.12111. Epub 2013 Jun 21.

Supplemental Content

Support Center